ArticleBMC neurology2026
Successful treatment of Anti-NF155 antibody positive autoimmune nodopathy with telitacicept: a case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune Nodopathy (AN) has been classified as an independent disease due to significant differences in pathological features and clinical manifestations from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), yet it is often overlooked or misdiagnosed. We report a case of neurofascin-155 (NF155) + AN in a 76-year-old male. Innovatively, we introduced the dual B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) inhibitor telitacicept as first-line therapy immediately after diagnosis. This therapeutic approach led to rapid and sustained disease control in the patient. Beyond demonstrating the critical importance of early diagnosis and targeted therapy in preventing irreversible neurological damage, this case provides compelling preliminary evidence for the favorable efficacy and safety of telitacicept, supporting its potential as a first-line treatment for AN, particularly in the NF155 + subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.